Keyword: Eleven Biotherapeutics
Sesen Bio presented three-month data showing that its bladder cancer drug Vicinium had a 43% complete response rate.
The change comes 20 months after the then-flailing biotech merged with Viventia Bio and refocused on oncology.
Eleven Bio is looking to come back to life after being on life support for much of 2016 with a merger deal combining it with Canadian company Viventia, who will take over at the top of the biotech.
Preclinical microcap Eleven Biotherapeutics hopes to press the reset button by refocusing on a Roche deal that could continue to offer infusions of cash, or be paid out to investors.
Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing the end.
Faced with back-to-back pivotal flops for its lead drug, Eleven Biotherapeutics has now outlicensed the second drug in its limited pipeline to Roche.